Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft lowered its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 55.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,000 shares of the company’s stock after selling 18,452 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Hims & Hers Health were worth $363,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Raleigh Capital Management Inc. increased its position in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. GAMMA Investing LLC grew its position in Hims & Hers Health by 2,173.7% in the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after buying an additional 2,152 shares in the last quarter. Quest Partners LLC raised its position in shares of Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after buying an additional 807 shares in the last quarter. CWM LLC lifted its stake in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares during the period. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 115.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock valued at $110,000 after acquiring an additional 2,442 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of research reports. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and increased their price target for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target for the company. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Needham & Company LLC increased their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $25.13.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,343 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total value of $70,055.70. Following the completion of the sale, the insider now directly owns 165,254 shares in the company, valued at $4,941,094.60. The trade was a 1.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick Harrison Carroll sold 15,000 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $22.07, for a total transaction of $331,050.00. Following the transaction, the insider now owns 196,941 shares in the company, valued at approximately $4,346,487.87. This trade represents a 7.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,256,067 shares of company stock valued at $34,459,485 in the last quarter. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Up 6.4 %

Shares of HIMS stock opened at $33.89 on Friday. The stock’s fifty day simple moving average is $28.96 and its 200-day simple moving average is $22.47. The company has a market capitalization of $7.40 billion, a price-to-earnings ratio of 77.01 and a beta of 1.31. Hims & Hers Health, Inc. has a 1-year low of $8.51 and a 1-year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.